💙 🔷 Not impressed by Big Tech in Q3? Explore these Blue Chip Bargains insteadExplore for free

CORRECTED-Serbia seeks bids for majority stake in troubled drugmaker

Published 2017-09-11, 09:36 a/m
© Reuters.  CORRECTED-Serbia seeks bids for majority stake in troubled drugmaker
BHC
-

(Corrects to remove Reuters Instrument Code FITO.BEL in first paragraph. Clarifies that Galenika AD is unlisted)

BELGRADE, Sept 1 (Reuters) - The Serbian government sought bids for a majority stake in indebted drugmaker Galenika AD after increasing its control in the unlisted company through a debt-for-equity swap last month.

The government has been trying to sell Galenika as part of efforts to privatise, shut or slim down unprofitable state firms under its 1.2 billion euro ($1.4 billion) loan deal with the International Monetary Fund, but the generic drugmaker' s heavy debts have discouraged investors.

In a tender published in a Serbian daily, the government is offering its entire 93-percent stake for sale. The starting price is a nominal one euro, but the new owner will have to repay 25 million euros of company debt.

Potential bidders will have until Oct. 2 to express their interest in buying a majority stake in Galenika, the tender said.

Last month, the government and state-run gas retailer Srbijagas took on a combined 14.7 billion dinars ($147 million) of Galenika's debt in exchange for an 8 percent stake, increasing their total share in the drugmaker to 93 percent. remaining seven percent of the shares belong to small shareholders.

The government tried to privatise Galenika in 2013 but the sole bidder, Canada's Valeant VRX.TO , pulled out, citing the hostility of local unions as one factor.

In February this year, Serbia failed to reach a deal with a group of foreign drugmakers on the sale of a 25 percent stake in Galenika. ($1 = 0.8410 euros) ($1 = 100.0800 Serbian dinars)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.